

## Recent Drug Developments and Law Update Hosted Remotely Via Zoom March 3<sup>rd</sup>, 2024

## **Program Coordinator:**

Sherrill Brown, DVM, Pharm. D., BCPS
Director, Drug Information Service
The University of Montana
College of Health Professions and Biomedical Science

## **PROGRAM DESCRIPTION:**

New drugs and new guideline recommendations continue to affect medical practice. This program will provide updates on management of heart failure with reduced ejection fraction (HFrEF) and treatment of pain and other care recommendations for end of life. Current recommendations for the respiratory syncytial virus vaccine will be presented. In addition, an update from the Montana Board of Pharmacy will be provided.

## **PROGRAM GOAL:**

The goal of this program is to discuss new drugs, to compare them to other agents in the same pharmacological and/or therapeutic class, and to discuss where these new agents fit into disease state management. In addition, an update of federal and Montana state pharmacy laws will be provided

Schedule	Topics/speaker(s)
7:45-8:00 am	Welcome announcements and pre-test
8:00-9:00 am	<ul> <li>"The rise of RSV: Empowering Pharmacists as Primary Immunizers", Ken Chatriand, PharmD</li> <li>At the conclusion of this presentation, pharmacists will be able to: <ol> <li>Explain common and rare complications of respiratory syncytial virus (RSV)</li> <li>Select appropriate RSV vaccination recommendations for a specific patient</li> </ol> </li> </ul>
9:00-10:00 am	<ul> <li>"HFrEF- GDMT: Update – SGLT2 inhibitors-are we better at treating heart failure?", Vince Colucci, PharmD, BCPS (Cardiology), AACC, CPP At the conclusion of this presentation, pharmacists will be able to: <ol> <li>Explain the Guideline Directed Medical Therapy, Class I, Level of Evidence A (i.e., first-line drugs) to manage heart failure with reduced ejection fraction (HFrEF) patients in the outpatient setting</li> <li>Develop a medication treatment plan and optimize the titration of the heart failure medications discussed in patients with a diagnosis of HFrEF</li> </ol> </li></ul>
10:00-10:10 am	Break

Schedule	Topics/speaker(s)
10:10-11:10 am	<ul> <li>"Board of Pharmacy Updates 2024", Marcie Bough, PharmD         At the conclusion of this presentation, pharmacists and pharmacy technicians will be able to:         <ol> <li>List legislative and regulatory changes impacting the practice of pharmacy in Montana</li> <li>Discuss Red Tape Relief efforts to update existing regulations/rules</li> </ol> </li> </ul>
11:10 am-12:10 pm	<ul> <li>"End of Life Care &amp; Pain Management", Rose Macklin, PharmD, BCPS</li> <li>At the conclusion of this presentation, pharmacists will be able to:</li> <li>1. Recommend one opioid patch appropriate for use and another patch not recommended for pain management at the end of life</li> <li>2. Explain the safe use and disposal of controlled medications in the home</li> </ul>
12:10-12:20 pm	Break
12:20-1:20 pm	"Using Buprenorphine to Treat Opioid Use Disorder", Brett Bell, MD, MPH  At the conclusion of this presentation, pharmacists will be able to:  1. Describe the evidence supporting buprenorphine for opioid use disorder  2. Explain the complexities of buprenorphine prescribing in the age of fentanyl
1:20-1:30 pm	Closure



Skaggs School of Pharmacy at The University of Montana is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based activity. The Universal Activity Number (UAN) for the Recent Drug Development portion is #0035-0000-24-014-L01-P and approved for 4 hours or .40 CEUs. The Universal Activity Number for the Law Update portion is #0035-0000-24-015-L03 P/T and approved for 1 hour or .10 CEUs. In order to receive credits, participants must sign in to the Zoom presentation, attend the program in its entirety, and complete the program evaluation. CE credits will be uploaded to CPE Monitor within 60-days after the program.

<u>Disclosure of Potential Conflicts of Interest:</u> Skaggs School of Pharmacy at the University of Montana did not receive payment or services from a third party for any aspect of this activity and has no relationships (financial or other) with entities or activities that could be perceived to influence, or that give the appearance of potentially influencing any portion of this activity.